Short term exacerbation risk and exhaled nitric oxide in COPD

Area of Science:

• Pulmonology
• Biomarkers
• Respiratory Medicine

Background:

• Chronic obstructive pulmonary disease (COPD) exacerbations lead to significant morbidity and healthcare costs.
• Predictive biomarkers for exacerbation risk are crucial for optimizing COPD management.
• Fractional exhaled nitric oxide (FeNO) is a potential non-invasive biomarker for airway inflammation.

Purpose of the Study:

• To evaluate baseline FeNO as a predictor of moderate and severe COPD exacerbations within a 90-day period.
• To assess the association between elevated FeNO levels and the risk of COPD exacerbations.
• To explore the utility of FeNO in stratifying COPD patients by exacerbation risk.

Main Methods:

• Prospective cohort study of COPD patients attending pulmonology clinics.
• Stratification of patients based on baseline FeNO levels (<20 ppb vs. ≥20 ppb).
• Analysis of time-to-first exacerbation using Kaplan-Meier curves and Cox proportional hazards models.

Main Results:

• 322 COPD patients were included; 102 had high baseline FeNO (≥20 ppb).
• Patients with high FeNO exhibited significantly shorter time to moderate/severe exacerbations.
• High FeNO was associated with a 3.01-fold increased risk of moderate/severe COPD exacerbations (p < 0.001).

Conclusions:

• Elevated baseline FeNO (≥20 ppb) is a significant predictor of short-term moderate and severe COPD exacerbations.
• FeNO can serve as a valuable biomarker for early risk stratification in COPD patients.
• Findings support the use of FeNO for tailoring interventions and optimizing management strategies in COPD.